<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Amgen Looks to Biomarkers to Boost Its Batting Average in Developing New Drugs</title>
	<atom:link href="http://www.xconomy.com/national/2008/08/07/amgen-looks-to-biomarkers-to-boost-its-batting-average-in-developing-new-drugs/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/national/2008/08/07/amgen-looks-to-biomarkers-to-boost-its-batting-average-in-developing-new-drugs/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 21 Nov 2009 22:30:41 -0600</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Amgen’s Seattle and Boston Teams Seek to Boost Biotech Hit Rate 20 to 30 Percent at Kerentech</title>
		<link>http://www.xconomy.com/national/2008/08/07/amgen-looks-to-biomarkers-to-boost-its-batting-average-in-developing-new-drugs/comment-page-1/#comment-86449</link>
		<dc:creator>Amgen’s Seattle and Boston Teams Seek to Boost Biotech Hit Rate 20 to 30 Percent at Kerentech</dc:creator>
		<pubDate>Sat, 10 Oct 2009 08:26:23 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=3738#comment-86449</guid>
		<description>[...] them through a battery of genetic tests, cell-based tests, animal tests, models of disease, and biomarker studies to see which types of people might respond to such a treatment. The goal is to test whether the candidates are safe, and whether there’s [...]</description>
		<content:encoded><![CDATA[<p>[...] them through a battery of genetic tests, cell-based tests, animal tests, models of disease, and biomarker studies to see which types of people might respond to such a treatment. The goal is to test whether the candidates are safe, and whether there’s [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: More data to look at - Personalized Medicine - The Medical Quack .... by Barbara Duck - emrupdate.com</title>
		<link>http://www.xconomy.com/national/2008/08/07/amgen-looks-to-biomarkers-to-boost-its-batting-average-in-developing-new-drugs/comment-page-1/#comment-25804</link>
		<dc:creator>More data to look at - Personalized Medicine - The Medical Quack .... by Barbara Duck - emrupdate.com</dc:creator>
		<pubDate>Tue, 12 Aug 2008 05:30:22 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=3738#comment-25804</guid>
		<description>[...] Amgen Looks to Biomarkers to Boost Its Batting Average in Developing New Drugs: Technorati Tags: Clincal Trials,genomics,Amgen,Biomarkers,Pharmaceuticals [...]</description>
		<content:encoded><![CDATA[<p>[...] Amgen Looks to Biomarkers to Boost Its Batting Average in Developing New Drugs: Technorati Tags: Clincal Trials,genomics,Amgen,Biomarkers,Pharmaceuticals [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: More data to look at &#171; A Man With A Ph.D.</title>
		<link>http://www.xconomy.com/national/2008/08/07/amgen-looks-to-biomarkers-to-boost-its-batting-average-in-developing-new-drugs/comment-page-1/#comment-25768</link>
		<dc:creator>More data to look at &#171; A Man With A Ph.D.</dc:creator>
		<pubDate>Mon, 11 Aug 2008 19:22:21 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=3738#comment-25768</guid>
		<description>[...] data to look&#160;at August 11, 2008 &#8212; Richard    by Shutr Amgen Looks to Biomarkers to Boost Its Batting Average in Developing New Drugs: [Via Xconomy [...]</description>
		<content:encoded><![CDATA[<p>[...] data to look&nbsp;at August 11, 2008 &#8212; Richard    by Shutr Amgen Looks to Biomarkers to Boost Its Batting Average in Developing New Drugs: [Via Xconomy [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
